Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 15Thoracic 2Head & Neck 2Gastrointestinal 2CNS 2Plasma cell 1Other solid neoplasm 1Other hematologic neoplasm 1Lymphoid 1Gynecologic 1Genitourinary 1Dermatologic 1

Conditions

Malignant Solid Neoplasm 1

Interventions

pembrolizumab 77Injections 67Carboplatin 38Nivolumab 31Pemetrexed 29Cisplatin 29Cyclophosphamide 25Specimen Handling 24Interviews as Topic 24tislelizumab 20atezolizumab 20Bevacizumab 20Paclitaxel 19fludarabine 16Standard of Care 16Practice Guidelines as Topic 16Docetaxel 16Ipilimumab 15toripalimab 14Educational Status 14Cetuximab 14Fluorouracil 13Oxaliplatin 12Etoposide 12olaparib 11durvalumab 11Methods 11Gemcitabine 11Early Intervention, Educational 11Drug Therapy 11

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
trastuzumab biosimilar HLX02 × Other solid neoplasm × 1 year × Clear all
NCT06136897 2026-05-29

Testing Trastuzumab and Pertuzumab in Patients With Higher Than Normal Copies of the HER2 Gene Found in Their Tumors (MATCH - Subprotocol J)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
35 enrolled 10 charts
Other solid neoplasm

Malignant Solid Neoplasm

Data powered by HemOnc (CC BY 4.0) Colophon âš¡